Physician profile
Robert J Elsen
NPI 1639212624
$3,625.96
in general payments reported to CMS, 2019-2025
22 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $363 · 2021: $492 · 2022: $147 · 2023: $203 · 2024: $374 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.52 | 2019-2025 | |
| Braintree Laboratories, INC. | $431.03 | 2019-2025 | Sutab, Suflave |
| Pfizer INC. | $354.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $336.44 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.65 | 2019-2021 | |
| Janssen Biotech, INC. | $240.95 | 2019-2025 | Stelara, Tremfya |
| Aimmune Therapeutics, INC. | $132.08 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $130.02 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $115.08 | 2020-2024 | |
| Ucb, INC. | $114.51 | 2019 | |
| Ferring Pharmaceuticals INC. | $100.10 | 2019-2020 | |
| Medtronic, INC. | $92.72 | 2024-2025 | Gi Genius |
| Merck Sharp & Dohme LLC | $64.26 | 2019-2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $56.76 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $49.37 | 2025 | Vegzelma |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $46.70 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $33.28 | 2020 | |
| Phathom Pharmaceuticals, INC. | $30.11 | 2025 | Voquezna |
| Sandoz INC. | $25.29 | 2023 | Hyrimoz |
| Amgen INC. | $24.86 | 2022 | |
| Ardelyx, INC. | $22.66 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $14.16 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Elsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.